Uploaded December 2024 | Updated September 2026, 3 weeks ago

---

Nicole Pfarr, Dipl.-Biol, discusses how an in-house comprehensive genomic profiling (CGP) including HRD provides fast turnaround to guide patient treatment and improves laboratory operational efficiency. Nicole Pfarr shares results of a study in pancreatic cancer, and the findings of HRD positive cases with and without BRCA mutations, and other alterations for targeted therapy.

Nicole Pfarr, Dipl.-Biol, is the head of the Molecular Pathology Diagnostic Unit and of the Next Generation Sequencing Research Facility at the Technical University of Munich, Germany.

Learn about CGP HRD in ovarian cancer: youtu.be/54yI7Sxvnfc?si=H2SeIgVR8NYpVdS2

Learn about in-house CGP and rare mutations: youtu.be/NErI9YCGcn4

Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

View customer spotlight videos
youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79

View Illumina webinars
youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ

View Illumina support videos
youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

LinkedIn: linkedin.com/company/illumina
X: https://x.com/illumina
Instagram: instagram.com/illuminainc
Facebook: facebook.com/illuminainc
TikTok: tiktok.com/@illuminainc

#HRD #CGP #Illumina